Corona-19 vaccines do not trigger autoantibodies
Scientific studies have shown that many patients who had to be treated for infection with the SARS-CoV-2 coronavirus developed autoantibodies. Can COVID-19 vaccines also trigger autoantibodies?
Many patients being treated in hospital for COVID-19 have autoantibodies in their blood. Various studies have shown this. Can vaccines against the SARS-CoV-2 coronavirus also trigger autoantibodies?
Does the strength of the immune response differ?
According to a recent Message scientists from the University Medicine Magdeburg have carried out two studies on COVID-19 vaccines in the last few months.
The researchers aimed to find out whether the strength of the immune response differs after different COVID-19 vaccine combinations and whether these vaccinations reprogram the immune system in such a way that a reaction against endogenous structures occurs through so-called autoantibodies.
In the worst case, these could lead to the destruction of the body’s own cells and organs, which, according to the experts, would require lengthy medical treatments.
The studies published in the journal “European Journal of Immunology‘ and on the medical preprint server ‘medRxiv“ were published, were coordinated by the Institute for Molecular and Clinical Immunology of the University Medical Center Magdeburg. Other partners were the Institute for Clinical Chemistry and Pathobiochemistry at the University Medical Center Magdeburg and the Institute for Immunology at the Hannover Medical School (MHH).
Concentrations of vaccine antibodies and autoantibodies
As explained in the release, the following drug combinations were analyzed in the studies: Two vaccinations with an mRNA or vector vaccine or the combination of a vector vaccine followed by an mRNA vaccine.
A total of 120 volunteers from the Medical Faculty and the University Hospital in Magdeburg took part in the studies. According to the individual vaccine combination, the employees were divided into three groups.
Four blood samples were taken from all participants, before the second vaccination and two or four weeks and four months after the second vaccination. This allowed the concentrations of the vaccine antibodies and autoantibodies to be determined and then statistically evaluated.
understand processes better
“In our studies, we were able to show that the induction of antibodies against SARS-CoV-2 was reduced by around 90 percent after two vaccinations with the vector vaccine from AstraZeneca compared to the other two groups. This is probably also associated with a significantly reduced protection against infection with the delta variant of SARS-CoV-2,” explains the Magdeburg immunologist and head of the Institute for Molecular and Clinical Immunology at the University Medical Center Magdeburg, Prof. Dr. medical Burkhart Schraven.
According to the scientists, this information is important in order to better understand the processes triggered by the new vaccines and to answer some open questions.
“We were able to show that none of the three vaccination strategies induces the production of autoantibodies in healthy test persons and accordingly no unwanted immune reaction against the own body takes place. This is a very important finding, as such autoimmune responses have been observed in the context of symptomatic COVID-19 infections and therefore there was a possibility that vaccination could trigger similar changes,” said the study’s first author, Dr. re. of course Christopher Tower. (ad)
Author and source information
This text corresponds to the specifications of medical specialist literature, medical guidelines and current studies and has been checked by medical professionals.
- University Medicine Magdeburg: COVID-19 vaccines do not trigger autoantibodies, (accessed: January 22, 2022), University Medicine Magdeburg
- Swantje I. Hammerschmidt, Christoph Thurm, Berislav Bošnjak, Günter Bernhardt, Annegret Reinhold, Stefanie Willenzon, Christiane Ritter, Dirk Reinhold, Burkhart Schraven, Reinhold Förster: Robust induction of neutralizing antibodies against the SARS-CoV-2 Delta variant after homologous Spikevax or heterologous Vaxzevria-Spikevax vaccination; in: European Journal of Immunology, (published: 06.12.2021), European Journal of Immunology
- Christoph Thurm, Annegret Reinhold, Katrin Borucki, Sascha Kahlfuss, Eugen Feist, Jens Schreiber, Dirk Reinhold, Burkhart Schraven: Anti-SARS-CoV-2 vaccination does not induce the formation of autoantibodies but provides humoral immunity following heterologous and homologous vaccination regimens: Results from a clinical and prospective study within professionals of a German University Hospital; in: medRxiv, (veröffentlicht: 01.11.2021), medRxiv
This article contains general advice only and should not be used for self-diagnosis or treatment. He can not substitute a visit at the doctor.